This Book >>

  • 189pp. Published April 2020
  • Scientific Research Publishing
  • Category: Medicine & Healthcare
  • ISBN: 978-1-61896-904-0
  • (Hardcover) USD 109.00
  • ISBN: 978-1-61896-903-3
  • (Paperback) USD 89.00
Authors/Editors Price: 40% off
Buy at: bookorder@scirp.org

Connect with SCIRP >>

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)
Home > Books > Advances in Ace Inhibitors
Advances in Ace Inhibitors
  • Description
  • Author(s) Information

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) are a class of medication used primarily for the treatment of high blood pressure and heart failure. They work by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart.

In the present book, fifteen typical literatures about advances in Ace Inhibitors published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on ACE inhibitors, angiotensin-converting enzyme and blood pressure, etc. We hope this book can demonstrate ACE inhibitors as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies
  • Chapter 2
    Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [ 111 In-DOTA]MG11—first estimates for clinical translation
  • Chapter 3
    Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
  • Chapter 4
    ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis
  • Chapter 5
    Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial
  • Chapter 6
    Bioreductive preparation of ACE inhibitors precursor (R)-2-hydroxy-4 phenylbutanoate esters: Recent advances and future perspectives
  • Chapter 7
    Current Treatment of Angioedema Induced by ACE Inhibitors
  • Chapter 8
    Rapid screening and identification of ACE inhibitors in snake venoms using at-line nanofractionation LC-MS
  • Chapter 9
    The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials
  • Chapter 10
    Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy – a randomized, double-blind, placebo-controlled trial
  • Chapter 11
    ACE inhibitory peptides in standard and fermented deer velvet: an in silico and in vitro investigation
  • Chapter 12
    Evaluation of ACE, α‑glucosidase, and lipase inhibitory activities of peptides obtained by in vitro digestion of selected species of edible insects
  • Chapter 13
    Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials Youxia Liu 1† , Xin
  • Chapter 14
    Twenty-five-year research progress in hookworm excretory/secretory products
  • Chapter 15
    Ageing-Time Dependent Changes of Angiotensin I-Converting Enzyme-Inhibiting Activity of Protein Hydrolysates Obtained from Dry-Cured Pork Loins Inoculated with Probiotic Lactic Acid Bacteria
  • Chapter 16
    Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
Readership: Students, academics, teachers and other people attending or interested in Ace Inhibitors.
comments powered by Disqus